Heron Therapeutics Inc to Host U.S. FDA Approval of ZYNRELEF™ - Conference Call Transcript
Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Heron Therapeutics conference call to discuss the FDA approval of ZYNRELEF. As a reminder, this conference is being recorded. Now I would like to turn over the call to David Szekeres, Executive Vice President, Chief Operating Officer. Sir, please go ahead.
Thank you, Ural. Good afternoon, everyone, and thank you for joining us. With me today from Heron are Barry Quart, Chief Executive Officer and Chairman; John Poyhonen, President and Chief Commercial Officer; Kimberly Manhard, Executive Vice President, Drug Development and Board Director; Chris Storgard, Chief Medical Officer; and Mike Mathews, Senior Vice President, Acute Care franchise.
For those of you participating via conference call, the slides are made available via webcast and can also be accessed by going to the Investor Relations page of our website.
Barry will provide introductory remarks and offer context around the FDA approval of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |